Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine SR in peri- and postmenopausal women with MDD
NCT00369343Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Pfizer. Primary endpoint: Hamilton Psychiatric Rating Scale for Depression at 8 weeks. Started Sep 2006; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00369343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369343.